# Phase II Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents

> **NCT00147160** · PHASE2 · COMPLETED · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 87 (estimated)

## Conditions studied

- Glioma

## Interventions

- **DRUG:** Temozolomide, Cisplatinum

## Key facts

- **NCT ID:** NCT00147160
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2006-07
- **Final completion:** 2007-12
- **Target enrollment:** 87 (ESTIMATED)
- **Last updated:** 2012-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00147160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00147160, "Phase II Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00147160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*